INTUITIVE SURGICAL INC (IUI1.DE) Fundamental Analysis & Valuation
FRA:IUI1 • US46120E6023
Current stock price
402.45 EUR
+13.6 (+3.5%)
Last:
This IUI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. IUI1.DE Profitability Analysis
1.1 Basic Checks
- In the past year IUI1 was profitable.
- IUI1 had a positive operating cash flow in the past year.
- Each year in the past 5 years IUI1 has been profitable.
- Each year in the past 5 years IUI1 had a positive operating cash flow.
1.2 Ratios
- IUI1's Return On Assets of 13.96% is amongst the best of the industry. IUI1 outperforms 95.24% of its industry peers.
- IUI1's Return On Equity of 16.02% is amongst the best of the industry. IUI1 outperforms 85.71% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 13.95%, IUI1 belongs to the top of the industry, outperforming 90.48% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for IUI1 is above the industry average of 10.21%.
- The 3 year average ROIC (12.43%) for IUI1 is below the current ROIC(13.95%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.96% | ||
| ROE | 16.02% | ||
| ROIC | 13.95% |
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
1.3 Margins
- With an excellent Profit Margin value of 28.38%, IUI1 belongs to the best of the industry, outperforming 98.41% of the companies in the same industry.
- IUI1's Profit Margin has improved in the last couple of years.
- IUI1 has a better Operating Margin (29.35%) than 96.83% of its industry peers.
- IUI1's Operating Margin has improved in the last couple of years.
- IUI1 has a better Gross Margin (66.00%) than 73.02% of its industry peers.
- IUI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.35% | ||
| PM (TTM) | 28.38% | ||
| GM | 66% |
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
2. IUI1.DE Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
- IUI1 has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for IUI1 has been increased compared to 5 years ago.
- IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 40.01 indicates that IUI1 is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 40.01, IUI1 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 40.01 |
ROIC/WACC1.56
WACC8.97%
2.3 Liquidity
- IUI1 has a Current Ratio of 4.87. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of IUI1 (4.87) is better than 93.65% of its industry peers.
- A Quick Ratio of 3.96 indicates that IUI1 has no problem at all paying its short term obligations.
- The Quick ratio of IUI1 (3.96) is better than 93.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.87 | ||
| Quick Ratio | 3.96 |
3. IUI1.DE Growth Analysis
3.1 Past
- IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.83%, which is quite impressive.
- The Earnings Per Share has been growing by 21.42% on average over the past years. This is a very strong growth
- The Revenue has grown by 20.51% in the past year. This is a very strong growth!
- Measured over the past years, IUI1 shows a quite strong growth in Revenue. The Revenue has been growing by 18.22% on average per year.
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
3.2 Future
- The Earnings Per Share is expected to grow by 13.58% on average over the next years. This is quite good.
- The Revenue is expected to grow by 12.90% on average over the next years. This is quite good.
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue Next Year15.83%
Revenue Next 2Y14.84%
Revenue Next 3Y14.56%
Revenue Next 5Y12.9%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. IUI1.DE Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 52.75, IUI1 can be considered very expensive at the moment.
- IUI1's Price/Earnings ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 63.49% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 26.91. IUI1 is valued rather expensively when compared to this.
- The Price/Forward Earnings ratio is 46.09, which means the current valuation is very expensive for IUI1.
- 68.25% of the companies in the same industry are cheaper than IUI1, based on the Price/Forward Earnings ratio.
- IUI1 is valuated expensively when we compare the Price/Forward Earnings ratio to 23.69, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.75 | ||
| Fwd PE | 46.09 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, IUI1 is valued a bit more expensive than 65.08% of the companies in the same industry.
- IUI1's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 67.18 | ||
| EV/EBITDA | 43.68 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
- IUI1 has an outstanding profitability rating, which may justify a higher PE ratio.
- IUI1's earnings are expected to grow with 14.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.65
PEG (5Y)2.46
EPS Next 2Y14.34%
EPS Next 3Y14.52%
5. IUI1.DE Dividend Analysis
5.1 Amount
- No dividends for IUI1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IUI1.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:IUI1 (4/8/2026, 7:00:00 PM)
402.45
+13.6 (+3.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-22 2026-01-22/amc
Earnings (Next)04-21 2026-04-21/amc
Inst Owners88.53%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap142.94B
Revenue(TTM)10.06B
Net Income(TTM)2.86B
Analysts79.02
Price Target527.49 (31.07%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.28%
Min EPS beat(2)9.85%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)10.81%
Min EPS beat(4)3.05%
Max EPS beat(4)18.71%
EPS beat(8)8
Avg EPS beat(8)11.52%
EPS beat(12)12
Avg EPS beat(12)8.73%
EPS beat(16)14
Avg EPS beat(16)6.39%
Revenue beat(2)2
Avg Revenue beat(2)2.19%
Min Revenue beat(2)2.17%
Max Revenue beat(2)2.22%
Revenue beat(4)4
Avg Revenue beat(4)1.83%
Min Revenue beat(4)1.09%
Max Revenue beat(4)2.22%
Revenue beat(8)5
Avg Revenue beat(8)1.43%
Revenue beat(12)7
Avg Revenue beat(12)0.96%
Revenue beat(16)9
Avg Revenue beat(16)0.46%
PT rev (1m)0%
PT rev (3m)0.74%
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)0.26%
EPS NY rev (1m)0%
EPS NY rev (3m)3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.75 | ||
| Fwd PE | 46.09 | ||
| P/S | 16.62 | ||
| P/FCF | 67.18 | ||
| P/OCF | 55.21 | ||
| P/B | 9.39 | ||
| P/tB | 9.6 | ||
| EV/EBITDA | 43.68 |
EPS(TTM)7.63
EY1.9%
EPS(NY)8.73
Fwd EY2.17%
FCF(TTM)5.99
FCFY1.49%
OCF(TTM)7.29
OCFY1.81%
SpS24.21
BVpS42.87
TBVpS41.94
PEG (NY)3.65
PEG (5Y)2.46
Graham Number85.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.96% | ||
| ROE | 16.02% | ||
| ROCE | 16.01% | ||
| ROIC | 13.95% | ||
| ROICexc | 20.73% | ||
| ROICexgc | 21.4% | ||
| OM | 29.35% | ||
| PM (TTM) | 28.38% | ||
| GM | 66% | ||
| FCFM | 24.75% |
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
ROICexc(3y)18.4%
ROICexc(5y)18.81%
ROICexgc(3y)19.07%
ROICexgc(5y)19.65%
ROCE(3y)14.27%
ROCE(5y)14.28%
ROICexgc growth 3Y2.03%
ROICexgc growth 5Y0.92%
ROICexc growth 3Y2.86%
ROICexc growth 5Y2.05%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
F-Score8
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 79.72% | ||
| Cap/Sales | 5.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 83.46% | ||
| Profit Quality | 87.21% | ||
| Current Ratio | 4.87 | ||
| Quick Ratio | 3.96 | ||
| Altman-Z | 40.01 |
F-Score8
WACC8.97%
ROIC/WACC1.56
Cap/Depr(3y)178.7%
Cap/Depr(5y)155.64%
Cap/Sales(3y)11.2%
Cap/Sales(5y)9.67%
Profit Quality(3y)61.68%
Profit Quality(5y)71.87%
High Growth Momentum
Growth
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
Revenue Next Year15.83%
Revenue Next 2Y14.84%
Revenue Next 3Y14.56%
Revenue Next 5Y12.9%
EBIT growth 1Y25.34%
EBIT growth 3Y22.76%
EBIT growth 5Y22.63%
EBIT Next Year35.56%
EBIT Next 3Y21.57%
EBIT Next 5Y17.26%
FCF growth 1Y91.03%
FCF growth 3Y37.49%
FCF growth 5Y16.85%
OCF growth 1Y25.49%
OCF growth 3Y26.68%
OCF growth 5Y15.34%
INTUITIVE SURGICAL INC / IUI1.DE Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 7 / 10 to IUI1.DE.
Can you provide the valuation status for INTUITIVE SURGICAL INC?
ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
What is the profitability of IUI1 stock?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 9 / 10.
How financially healthy is INTUITIVE SURGICAL INC?
The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 9 / 10.
What is the expected EPS growth for INTUITIVE SURGICAL INC (IUI1.DE) stock?
The Earnings per Share (EPS) of INTUITIVE SURGICAL INC (IUI1.DE) is expected to grow by 14.45% in the next year.